These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 30927979)
21. Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis. Krashin E; Dolberg OJ; Hellmann I; Huitema AD; Rosing H; Ellis M Anticancer Drugs; 2016 Sep; 27(8):800-3. PubMed ID: 27254285 [TBL] [Abstract][Full Text] [Related]
22. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia. Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734 [TBL] [Abstract][Full Text] [Related]
23. Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics. Asghari H; Talati C Curr Opin Hematol; 2020 Mar; 27(2):66-75. PubMed ID: 31922971 [TBL] [Abstract][Full Text] [Related]
24. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Chen EC; Fathi AT; Brunner AM Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134 [TBL] [Abstract][Full Text] [Related]
25. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Murphy T; Yee KWL Expert Opin Pharmacother; 2017 Nov; 18(16):1765-1780. PubMed ID: 29017371 [TBL] [Abstract][Full Text] [Related]
26. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340 [TBL] [Abstract][Full Text] [Related]
27. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. Pluta A; Robak T; Wrzesien-Kus A; Katarzyna Budziszewska B; Sulek K; Wawrzyniak E; Czemerska M; Zwolinska M; Golos A; Holowiecka-Goral A; Kyrcz-Krzemien S; Piszcz J; Kloczko J; Mordak-Domagala M; Lange A; Razny M; Madry K; Wiktor-Jedrzejczak W; Grosicki S; Butrym A; Kuliczkowski K; Warzocha K; Holowiecki J; Giebel S; Szydlo R; Wierzbowska A Am J Hematol; 2017 Apr; 92(4):359-366. PubMed ID: 28103640 [TBL] [Abstract][Full Text] [Related]
28. Diagnosis and treatment of therapy-related acute myeloid leukemia. Strickland SA; Vey N Crit Rev Oncol Hematol; 2022 Mar; 171():103607. PubMed ID: 35101585 [TBL] [Abstract][Full Text] [Related]
29. [Acute myeloid leukemia of the elderly: recent progresses in therapy]. Yamauchi T Rinsho Ketsueki; 2018; 59(6):735-740. PubMed ID: 29973453 [TBL] [Abstract][Full Text] [Related]
30. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963 [TBL] [Abstract][Full Text] [Related]
31. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis. Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727 [TBL] [Abstract][Full Text] [Related]
32. Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes. Jensen IS; Wu E; Sacks NC; Cyr PL; Chung KC Am Health Drug Benefits; 2018 Oct; 11(7):380-386. PubMed ID: 30647825 [TBL] [Abstract][Full Text] [Related]
33. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation. Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918 [TBL] [Abstract][Full Text] [Related]
34. Current and emerging therapies for acute myeloid leukemia. Robak T; Wierzbowska A Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045 [TBL] [Abstract][Full Text] [Related]
35. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823 [TBL] [Abstract][Full Text] [Related]
37. CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. Hu Y; Caldwell KJ; Onciu M; Federico SM; Salek M; Lewis S; Lei S; Zhang J; Nichols KE; Takemoto CM; Triplett BM; Farrar JE; Rubnitz JE; Ribeiro RC; Wlodarski MW Blood Adv; 2022 Jan; 6(2):521-527. PubMed ID: 34710216 [TBL] [Abstract][Full Text] [Related]
38. Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia. Choi EJ; Lee JH; Lee JH; Park HS; Ko SH; Hur EH; Moon J; Goo BK; Kim Y; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH Leuk Res; 2018 May; 68():51-56. PubMed ID: 29544132 [TBL] [Abstract][Full Text] [Related]
39. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. Ossenkoppele G; Montesinos P Crit Rev Oncol Hematol; 2019 Jun; 138():6-13. PubMed ID: 31092386 [TBL] [Abstract][Full Text] [Related]